News
Dose-dense MVAC credited with better bladder cancer survival
Response rates and overall survival were better with dose-dense MVAC vs. gemcitabine and a platinum compound in muscle-invasive disease.
News
Nab-paclitaxel/gemcitabine may be alternative treatment for cholangiocarcinoma
Despite failure to prove its hypothesis, a phase 2 trial suggested that nab-paclitaxel/gemcitabine may offer efficacy comparable to that of...
News
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
News
Lurbinectedin shows activity against relapsed Ewing’s
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration,...
News
Renal hemangioma? Think again
Tumor morphology suggested the presence of a renal hemangioma but staining produced mixed signals, pathologists reported.
News
First-ever gestational trophoblastic neoplasia guidelines published
These rare tumors of pregnancy are generally curable with the appropriate risk-based therapies, experts say.
News
Variants in five genes signal TNBC risk
Risks for triple-negative breast cancer associated with pathogenic variants in five genes ranged from about 5.5-fold to nearly 17-fold.
News
CT features associated with (some) ccRCC subtypes
Radiogenomic analysis showed that well-defined tumor margins and other features were associated with specific clinical presentations.
News
Insurance status linked to survival in FL patients
Having health insurance can mean the difference between life and death for US patients with follicular lymphoma (FL), according to research...
News
Adjuvant chemotherapy benefits high-risk sarcoma patients
Chemotherapy halved the risk of disease progression and death for patients with low probability of 10-year overall survival.
News
Sonic hedgehog inhibitors have mixed efficacy for advanced BCC
Vismodegib was associated with a higher complete response rate than sonidegib in patients with locally advanced basal cell carcinoma.
News
Rapid drug alteration a bust in metastatic GIST
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
News
ctDNA profiles pre- and posttreatment KIT mutations in GIST
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
News
Novel TKI PLX9486 showed efficacy against KIT mutations in GIST
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
News
Low response rate with trofosfamide for advanced STS in elderly
CHICAGO – Of 80 patients with previously untreated metastatic soft-tissue sarcomas, 2 had complete, durable responses to oral trofosfamide.